Literature DB >> 10910910

A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.

M Jacquemin1, R Lavend'homme, A Benhida, B Vanzieleghem, R d'Oiron, J M Lavergne, H H Brackmann, R Schwaab, T VandenDriessche, M K Chuah, M Hoylaerts, J G Gilles, K Peerlinck, J Vermylen, J M Saint-Remy.   

Abstract

The mechanisms responsible for the low factor VIII (fVIII) activity in the plasma of patients with mild/moderate hemophilia A are poorly understood. In such patients, we have identified a series of fVIII mutations (Ile2098Ser, Ser2119Tyr, Asn2129Ser, Arg2150His, and Pro2153Gln) clustered in the C1 domain and associated with reduced binding of fVIII to von Willebrand factor (vWf). For each patient plasma, the specific activity of mutated fVIII was close to that of normal fVIII. Scatchard analysis showed that the affinity for vWf of recombinant Ile2098Ser, Ser2119Tyr, and Arg2150His fVIII mutants was reduced 8-fold, 80-fold, and 3-fold, respectively, when compared with normal fVIII. Given the importance of vWf for the stability of fVIII in plasma, these findings suggested that the reduction of fVIII binding to vWf resulting from the above-mentioned mutations could contribute to patients' low fVIII plasma levels. We, therefore, analyzed the effect of vWf on fVIII production by Chinese hamster ovary (CHO) cells transfected with expression vectors for recombinant B domain-deleted normal, Ile2098Ser, Ser2119Tyr, and Arg2150His fVIII. These 3 mutations impaired the vWf-dependent accumulation of functional fVIII in culture medium. Analysis of fVIII production by transiently transfected CHO cells indicated that, in addition to the impaired stabilization by vWf, the secretion of functional Ile2098Ser and Arg2150His fVIII was reduced about 2-fold and 6-fold, respectively, by comparison to Ser2119Tyr and normal fVIII. These findings indicate that C1-domain mutations resulting in reduced fVIII binding to vWf are an important cause of mild/moderate hemophilia A.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910910

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.

Authors:  Laura L Swystun; Colleen Notley; Ilinca Georgescu; Jesse D Lai; Kate Nesbitt; Paula D James; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

2.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Authors:  Joerg Kahle; Aleksander Orlowski; Diana Stichel; John F Healey; Ernest T Parker; Marc Jacquemin; Manuela Krause; Andreas Tiede; Dirk Schwabe; Pete Lollar; Christoph Königs
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

3.  FVIII-VWF dos-à-dos.

Authors:  Sriram Krishnaswamy
Journal:  Blood       Date:  2015-08-20       Impact factor: 22.113

4.  Inhibitor development in two patients with mild haemophilia A - spontaneous disappearance and no recurrence of the inhibitor after re-challenge.

Authors:  Sylvia Reitter-Pfoertner; Birgit Horvath; Klaus Lechner; Raute Sunder-Plassmann; Christine Mannhalter; Ingrid Pabinger
Journal:  Wien Klin Wochenschr       Date:  2012-01-18       Impact factor: 1.704

5.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Authors:  Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier
Journal:  Haemophilia       Date:  2016-01       Impact factor: 4.287

Review 6.  Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management.

Authors:  Gary Benson; Günter Auerswald; Gerry Dolan; Anne Duffy; Cedric Hermans; Rolf Ljung; Massimo Morfini; Silva Zupančić Šalek
Journal:  Blood Transfus       Date:  2017-11-14       Impact factor: 3.443

7.  Molecular mechanisms of missense mutations that generate ectopic N-glycosylation sites in coagulation factor VIII.

Authors:  Wei Wei; Saurav Misra; Matthew V Cannon; Renchi Yang; Xiaofan Zhu; Reid Gilmore; Min Zhu; Bin Zhang
Journal:  Biochem J       Date:  2018-03-06       Impact factor: 3.857

8.  Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Coagul Disord       Date:  2010-07-01

9.  Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.

Authors:  Wojciech Jankowski; Yara Park; Joseph McGill; Eugene Maraskovsky; Marco Hofmann; Vincent P Diego; Bernadette W Luu; Tom E Howard; Roberta Kellerman; Nigel S Key; Zuben E Sauna
Journal:  Blood Adv       Date:  2019-05-14

Review 10.  Blood coagulation factor VIII: An overview.

Authors:  G M Bhopale; R K Nanda
Journal:  J Biosci       Date:  2003-12       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.